Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.9% from 2024 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
The gene induced immunotherapy segment held the largest share in 2023 due to increase in the advancement in gene induced immunotherapy research
Biopharmaceutical companies held the largest market share in 2023 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
North America dominated the market in 2023 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Product Code: GVR-4-68039-984-2

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Therapy
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. High growth of the pharmaceutical industry
  - 3.2.1.2. Rising R&D investments and demand for novel cancer therapeutics
  - 3.2.1.3. Increased incidence of cancers
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High product prices
  - 3.2.2.2. Unethical use of gene therapy
3.3. Cancer Gene Therapy Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Cancer Gene Therapy Market: Therapy Movement Analysis
4.3. Cancer Gene Therapy Market by Therapy Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Oncolytic Virotherapy
- 4.5.1. Oncolytic Virotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Gene Induced Immunotherapy
- 4.6.1. Gene Induced Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Gene Transfer
- 4.7.1. Gene Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Cancer Gene Therapy Market: End Use Movement Analysis
5.3. Cancer Gene Therapy Market by End Use Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Research Institutes
- 5.5.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Biopharmaceutical Companies
- 5.6.1. Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Diagnostic Centers
- 5.7.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use

6.1. Regional Dashboard
6.2. Regional Cancer Gene Therapy Market Movement Analysis
6.3. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Technology & End Use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
- 6.5.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. U.S.
  - 6.5.2.1. Key Country Dynamics
  - 6.5.2.2. Competitive Scenario
  - 6.5.2.3. Regulatory Framework
  - 6.5.2.4. Reimbursement scenario
  - 6.5.2.5. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Canada
  - 6.5.3.1. Key Country Dynamics
  - 6.5.3.2. Competitive Scenario
  - 6.5.3.3. Regulatory Framework
  - 6.5.3.4. Reimbursement scenario
  - 6.5.3.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. Mexico
  - 6.5.4.1. Key Country Dynamics
  - 6.5.4.2. Competitive Scenario
  - 6.5.4.3. Regulatory Framework
  - 6.5.4.4. Reimbursement scenario
  - 6.5.4.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Europe
- 6.6.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. UK
  - 6.6.2.1. Key Country Dynamics
  - 6.6.2.2. Competitive Scenario
  - 6.6.2.3. Regulatory Framework
  - 6.6.2.4. Reimbursement scenario
  - 6.6.2.5. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Germany
  - 6.6.3.1. Key Country Dynamics
  - 6.6.3.2. Competitive Scenario
  - 6.6.3.3. Regulatory Framework
  - 6.6.3.4. Reimbursement scenario
  - 6.6.3.5. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. Switzerland
  - 6.6.4.1. Key Country Dynamics
  - 6.6.4.2. Competitive Scenario
  - 6.6.4.3. Regulatory Framework
  - 6.6.4.4. Reimbursement scenario
  - 6.6.4.5. Switzerland Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Asia Pacific
- 6.7.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.2. Japan
  - 6.7.2.1. Key Country Dynamics
  - 6.7.2.2. Competitive Scenario
  - 6.7.2.3. Regulatory Framework
  - 6.7.2.4. Reimbursement scenario
  - 6.7.2.5. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. China
  - 6.7.3.1. Key Country Dynamics
  - 6.7.3.2. Competitive Scenario
  - 6.7.3.3. Regulatory Framework
  - 6.7.3.4. Reimbursement scenario
  - 6.7.3.5. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.4. Australia
  - 6.7.4.1. Key Country Dynamics
  - 6.7.4.2. Competitive Scenario
  - 6.7.4.3. Regulatory Framework
  - 6.7.4.4. Reimbursement scenario
  - 6.7.4.5. Australia Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Rest of World
- 6.8.1. Latin America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Market Participant Categorization
7.2. Key Company Profiles
- 7.2.1. Abeona Therapeutics Inc.
  - 7.2.1.1. Company overview
  - 7.2.1.2. Financial performance
  - 7.2.1.3. Product benchmarking
  - 7.2.1.4. Strategic initiatives
- 7.2.2. Asklepios BioPharmaceutical Inc.
  - 7.2.2.1. Company overview
  - 7.2.2.2. Financial performance
  - 7.2.2.3. Product benchmarking
  - 7.2.2.4. Strategic initiatives
- 7.2.3. Altor Bioscience Inc.
  - 7.2.3.1. Company overview
  - 7.2.3.2. Financial performance
  - 7.2.3.3. Product benchmarking
  - 7.2.3.4. Strategic initiatives
- 7.2.4. Bluebird bio Inc.
  - 7.2.4.1. Company overview
  - 7.2.4.2. Financial performance
  - 7.2.4.3. Product benchmarking
  - 7.2.4.4. Strategic initiatives
- 7.2.5. BioCancell Inc.
  - 7.2.5.1. Company overview
  - 7.2.5.2. Financial performance
  - 7.2.5.3. Product benchmarking
  - 7.2.5.4. Strategic initiatives
- 7.2.6. CelgeneInc.
  - 7.2.6.1. Company overview
  - 7.2.6.2. Financial performance
  - 7.2.6.3. Product benchmarking
  - 7.2.6.4. Strategic initiatives
- 7.2.7. Elevate BioInc.
  - 7.2.7.1. Company overview
  - 7.2.7.2. Financial performance
  - 7.2.7.3. Product benchmarking
  - 7.2.7.4. Strategic initiatives
- 7.2.8. GlaxoSmithKlineInc.
  - 7.2.8.1. Company overview
  - 7.2.8.2. Financial performance
  - 7.2.8.3. Product benchmarking
  - 7.2.8.4. Strategic initiatives
- 7.2.9. Genelux Corporation
  - 7.2.9.1. Company overview
  - 7.2.9.2. Financial performance
  - 7.2.9.3. Product benchmarking
  - 7.2.9.4. Strategic initiatives
- 7.2.10. GenVec
  - 7.2.10.1. Company overview
  - 7.2.10.2. Financial performance
  - 7.2.10.3. Product benchmarking
  - 7.2.10.4. Strategic initiatives
- 7.2.11. Introgen TherapeuticsInc.
  - 7.2.11.1. Company overview
  - 7.2.11.2. Financial performance
  - 7.2.11.3. Product benchmarking
  - 7.2.11.4. Strategic initiatives
- 7.2.12. OncoGenex Pharmaceuticals Inc.
  - 7.2.12.1. Company overview
  - 7.2.12.2. Financial performance
  - 7.2.12.3. Product benchmarking
  - 7.2.12.4. Strategic initiatives

Product Code: GVR-4-68039-984-2

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 4 Global cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America cancer gene therapy market, by region, 2018 - 2030 (USD Million)
Table 6 North America cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 7 North America cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 8 U.S. cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 9 U.S. cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 10 Canada cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 11 Canada cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 12 Mexico cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 13 Mexico cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 14 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 15 Europe cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 16 Europe cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 17 UK cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 18 UK cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 19 Germany cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 20 Germany cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 21 Switzerland cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 22 Switzerland cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 23 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 25 Asia Pacific cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 26 Japan cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 27 Japan cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 28 China cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 29 China cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 30 Australia cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 31 Australia cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
Table 32 Rest of World cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
Table 33 Rest of World cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Information Procurement Primary Research Pattern
Fig. 2 Market Research Approaches
Fig. 3 Value Chain-Based Sizing & Forecasting
Fig. 4 Market Formulation & Validation
Fig. 5 Market driver analysis
Fig. 6 Market restraint analysis
Fig. 7 PESTEL Analysis
Fig. 8 Porter's Five Forces Analysis
Fig. 9 Cancer gene therapy market, therapy outlook key takeaways (USD Million)
Fig. 10 Cancer gene therapy market: Therapy movement analysis 2023 & 2030 (USD Million)
Fig. 11 Oncolytic Virotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 12 Gene induced immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 13 Gene transfer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Cancer gene therapy market, end use outlook key takeaways (USD Million)
Fig. 15 Cancer gene therapy market: End use movement analysis (USD Million), 2023 & 2030
Fig. 16 Research institutes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Biopharmaceutical companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Cancer gene therapy market: Regional key takeaways (USD Million)
Fig. 21 Cancer gene therapy market: regional outlook, 2023 & 2030 (USD Million)
Fig. 22 North America cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 U.S. cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Canada cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Mexico cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Europe cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 UK cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Germany cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Switzerland cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Asia Pacific cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 China cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Japan cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Australia cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Rest of World cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030

Description

Table of Contents

List of Tables

Cancer Gene Therapy Market Growth & Trends:

Cancer Gene Therapy Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use

Chapter 7. Competitive Landscape

List of Tables

List of Figures